Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities
Open Access
- 1 June 2016
- journal article
- Published by Elsevier in Applied & Translational Genomics
- Vol. 9, 3-5
Abstract
No abstract availableFunding Information
- Institute for Cellular and Molecular Medicine
- University of Pretoria
This publication has 25 references indexed in Scilit:
- Role of pharmacogenomics in the treatment of tuberculosis: a reviewPharmacogenomics and Personalized Medicine, 2012
- A prospective study of adverse drug reactions to artemisinin-based combination therapy in a tertiary care hospital in IndiaIndian Journal of Pharmacology, 2012
- Can pharmacogenomics improve malaria drug policy?Bulletin of the World Health Organization, 2011
- Human Genetic Variation Is Associated With Plasmodium falciparum Drug ResistanceThe Journal of Infectious Diseases, 2011
- The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing ImplicationsAntimicrobial Agents and Chemotherapy, 2011
- Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patientsBritish Journal of Clinical Pharmacology, 2011
- Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian populationBMC Medical Genetics, 2009
- Adverse Effects of Highly Active Antiretroviral Therapy in Developing CountriesClinical Infectious Diseases, 2007
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Management of the Adverse Effects of Antiretroviral Therapy and Medication AdherenceClinical Infectious Diseases, 2000